Abstract:
ObjectiveTo explore the effect of long-chain non-coding RNA eosinophilic transcription factor (EGOT) on lipopolysaccharide (LPS) -induced apoptosis and inflammation of alveolar epithelial A549 cells and its possible mechanism.
MethodsA549 cells were divided into control (Con) group, LPS group, LPS+pcDNA group, LPS+pcDNA-EGOT group, LPS+anti-miR-NC group, LPS+anti-miR-320a group, LPS+pcDNA-EGOT+miR-NC group, and LPS+pcDNA-EGOT+miR-320a group.Real-time quantitative PCR (RT-qPCR) was used to detect the expression levels of EGOT and miR-320a, flow cytometry was applied to detect apoptosis, and the kit was used to detect the levels of interleukin (IL) -6 and IL-1β.Dual luciferase reporter gene assay and RT-qPCR was employed to confirm the targeting relationship between EGOT and miR-320a.
ResultsCompared with the Con group, the apoptosis rate, IL-6 and IL-1β levels of A549 cells in the LPS group were increased(P < 0.01), the EGOT expression level was reduced(P < 0.05), and the miR-320a expression level was significantly increased (P < 0.01).Compared with the LPS+pcDNA group, the apoptosis rate, Bax protein expression, IL-6 and IL-1β levels of A549 cells in the LPS+pcDNA-EGOT group were reduced(P < 0.05), and the Bcl-2 protein expression were increased(P < 0.05).Compared with the LPS+anti-miR-NC group, the apoptosis rate, Bax protein expression, IL-6 and IL-1β levels of A549 cells in the LPS+anti-miR-320a group were significantly reduced(P < 0.01), and the Bcl-2 protein expression were significantly increased(P < 0.01).Compared with the LPS+pcDNA-EGOT+miR-NC group, the apoptosis rate, Bax protein expression, IL-6 and IL-1β levels of A549 cells in the LPS+pcDNA-EGOT+miR-320a group were significantly increased (P < 0.01), and the Bcl-2 protein expression were significantly reduced (P < 0.01).The results of dual luciferase reporter gene assay showed that EGOT targeted and negatively regulated the miR-320a expression.
ConclusionsLncRNA EGOT can alleviate LPS-induced inflammation and apoptosis of alveolar epithelial cells by targeting miR-320a.